Labcorp Holdings Inc
Labcorp Holdings Inc (LH) is listed on NYSE and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Burlington, United States and has 71,000 employees. The company is worth $26.76B and trades at 27.3x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $13.95B in fiscal 2025, up 7.2% from the year before. Net income was $876.5M. The share price is 3.5% below its 52-week high of $341.80. It pays a dividend yielding 0.87%. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $63.85M. In that quarter, 2 of them opened or added to the position and 3 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +29.7% over 5Y.
today you would have $1,359.81▲ +36.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 19 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $250.88 | $229.32 | $227.29 | $202.30 | $269.94 | $174.87 | $145.34 | $108.56 | $137.04 | $110.29 | $106.22 | $92.70 | $78.50 | $74.42 | $73.86 | $75.53 | $64.30 | $55.34 | $64.89 | |
| P/E | 16.6x | 24.0x | 25.9x | 47.6x | 14.5x | 11.1x | 12.8x | 20.3x | 14.7x | 13.5x | 18.8x | 28.4x | 18.3x | 14.6x | 14.5x | 16.8x | 16.6x | 15.0x | 15.5x | 19.2x |
| P/S | 1.5x | 1.5x | 1.5x | 1.6x | 1.8x | 2.2x | 1.4x | 1.4x | 1.1x | 1.6x | 1.4x | 1.4x | 1.8x | 1.3x | 1.4x | 1.5x | 1.8x | 1.7x | 1.5x | — |
| P/B | 2.4x | 2.4x | 2.4x | 2.4x | 2.1x | 2.9x | 2.1x | 2.2x | 1.8x | 2.4x | 2.4x | 2.5x | 3.8x | 3.1x | 1.6x | 3.3x | 3.6x | 3.7x | 4.1x | — |
| EPS | $10.46 | $8.84 | $4.77 | $13.97 | $24.39 | $13.64 | $7.17 | $7.40 | $10.15 | $5.86 | $3.74 | $5.08 | $5.37 | $5.15 | $4.39 | $4.54 | $4.28 | $3.57 | $3.38 | |
| Dividend yield | 1.16% | 1.15% | 1.26% | 1.18% | 0.92% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Payout | 30.06% | 27.53% | 32.58% | 56.12% | 13.28% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Profit margin | 9.88% | 6.28% | 5.73% | 3.44% | 10.78% | 18.10% | 11.13% | 7.13% | 7.80% | 11.90% | 7.45% | 5.04% | 8.50% | 9.88% | 10.28% | 9.38% | 11.16% | 11.57% | 10.31% | 11.72% |
| ROE | 16.49% | 10.17% | 9.26% | 5.31% | 12.67% | 23.14% | 16.49% | 10.78% | 12.54% | 18.03% | 12.90% | 8.85% | 18.12% | 23.03% | 11.79% | 20.76% | 22.63% | 25.80% | 27.51% | 27.64% |
Median of the years shown; P/E years above 200x are left out.
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
Median P/E of 16.6 across this company’s own years on record.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
5 methods answered, across 3 families.
Room for errors in the reported numbers.
-30.1% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DGXQuest Diagnostics Inc | $243.28 | 25.8x | 3.6x | 1.41% | 14.60% | $26.85B |
| ROIVRoivant Sciences Ltd. | $37.45 | — | 6.4x | 0.00% | -8.52% | $27.05B |
| PHGKoninklijke Philips NV | $26.92 | 20.1x | 2.0x | 3.75% | 10.15% | $26.31B |
| WSTWest Pharmaceutical Services Inc | $394.03 | 50.5x | 9.3x | 0.22% | 19.09% | $27.73B |
| UTHRUNITED THERAPEUTICS Corp | $584.79 | 20.9x | 3.9x | 0.00% | 19.32% | $25.08B |
| GMABGenmab A/s | $40.00 | 31.5x | 4.0x | 0.00% | 14.00% | $24.6B |